SC
BHVN

Saturna Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Saturna Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,350
Closed -$204K – 164
2022
Q3 		$204K Sell
1,350
-130
-9% -$19.3K 0.01% 150
2022
Q2 		$216K Sell
1,480
-270
-15% -$34.5K 0.01% 149
2022
Q1 		$207K Sell
1,750
-330
-16% -$41.2K ﹤0.01% 163
2021
Q4 		$287K Buy
2,080
+40
+2% +$5.09K 0.01% 154
2021
Q3 		$283K Buy
+2,040
New +$255K 0.01% 157

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Saturna Capital's BHVN Position: Q4 2022 in Review

Saturna Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,350 shares — an estimated $204K sold.

Saturna Capital first reported a position in BHVN in Q3 2021 and held it in 5 quarters. The position peaked at $287K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Saturna Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Saturna Capital sold 1,350 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $204K.
  • Saturna Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 5 quarters.
  • Saturna Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $287K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Saturna Capital's 13F filing for Q4 2022, filed 9 Feb 2023.